CA2859859A1 - Dispositifs d'administration transmucosale de medicament pour une utilisation dans le soulagement de la douleur chronique - Google Patents

Dispositifs d'administration transmucosale de medicament pour une utilisation dans le soulagement de la douleur chronique Download PDF

Info

Publication number
CA2859859A1
CA2859859A1 CA2859859A CA2859859A CA2859859A1 CA 2859859 A1 CA2859859 A1 CA 2859859A1 CA 2859859 A CA2859859 A CA 2859859A CA 2859859 A CA2859859 A CA 2859859A CA 2859859 A1 CA2859859 A1 CA 2859859A1
Authority
CA
Canada
Prior art keywords
subject
buprenorphine
pain
buffered
mucoadhesive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2859859A
Other languages
English (en)
Inventor
Andrew Finn
Niraj Vasisht
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biodelivery Sciences International Inc
Original Assignee
Biodelivery Sciences International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biodelivery Sciences International Inc filed Critical Biodelivery Sciences International Inc
Publication of CA2859859A1 publication Critical patent/CA2859859A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Abstract

L'invention concerne des procédés de traitement de la douleur chronique par administration de faibles doses de buprénorphine deux fois par jour (ou une fois par jour) par un dispositif d'administration transmucosale de médicament. Les procédés et dispositifs traitent efficacement la douleur chronique sans effets secondaires significatifs.
CA2859859A 2011-12-21 2012-12-21 Dispositifs d'administration transmucosale de medicament pour une utilisation dans le soulagement de la douleur chronique Abandoned CA2859859A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161578755P 2011-12-21 2011-12-21
US61/578,755 2011-12-21
PCT/US2012/071330 WO2013096811A2 (fr) 2011-12-21 2012-12-21 Dispositifs d'administration transmucosale de médicament pour une utilisation dans le soulagement de la douleur chronique

Publications (1)

Publication Number Publication Date
CA2859859A1 true CA2859859A1 (fr) 2013-06-27

Family

ID=48669710

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2859859A Abandoned CA2859859A1 (fr) 2011-12-21 2012-12-21 Dispositifs d'administration transmucosale de medicament pour une utilisation dans le soulagement de la douleur chronique

Country Status (16)

Country Link
EP (1) EP2793870A4 (fr)
JP (1) JP6255349B2 (fr)
KR (4) KR20190110628A (fr)
CN (2) CN110123792A (fr)
AU (4) AU2012358308A1 (fr)
BR (1) BR112014015329A8 (fr)
CA (1) CA2859859A1 (fr)
EA (2) EA201992762A1 (fr)
HK (1) HK1203365A1 (fr)
IL (2) IL233075A0 (fr)
IN (1) IN2014DN06117A (fr)
MX (2) MX362217B (fr)
SG (3) SG10201710667YA (fr)
UA (1) UA118540C2 (fr)
WO (1) WO2013096811A2 (fr)
ZA (1) ZA201804381B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021163529A2 (fr) * 2020-02-13 2021-08-19 Biodelivery Sciences International, Inc. Procédés de traitement avec de la buprénorphine

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800832A (en) 1996-10-18 1998-09-01 Virotex Corporation Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
DE19652188C2 (de) * 1996-12-16 2002-02-14 Lohmann Therapie Syst Lts Flache Arzneizubereitung zur Applikation und Freisetzung von Buprenorphin oder einer pharmakologisch vergleichbaren Substanz in der Mundhöhle und Verfahren zu ihrer Herstellung
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
DE19960154A1 (de) * 1999-12-14 2001-07-12 Lohmann Therapie Syst Lts Flache Arzneizubereitung zur transmucosalen Verabreichung von Oxycodon oder einem vergleichbaren Wirkstoff in der Mundhöhle, für die Anwendung in der Schmerztherapie und Suchttherapie
CN1423559A (zh) * 2000-02-08 2003-06-11 欧罗赛铁克股份有限公司 包含阿片样激动剂和拮抗剂的控释组合物
EP1389621A4 (fr) 2001-04-27 2005-05-11 Ajinomoto Kk Derives pyrazolyl-o-glycoside n-substitues et medicament contre le diabete en contenant
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
DE102005007859A1 (de) * 2005-02-21 2006-08-24 Lts Lohmann Therapie-Systeme Ag Vefahren für eine medikamentöse Kombinations-Behandlung, sowie hierfür geeignete Arzneimittel-Kombinationen
US20060281775A1 (en) * 2005-06-14 2006-12-14 Applied Pharmacy Services, Inc. Two-component pharmaceutical composition for the treatment of pain
BRPI0619806A2 (pt) 2005-12-13 2011-10-18 Biodelivery Sciences Int Inc dispositivo para fornecimento de fármacos transmucosal resistente ao abuso
CA2649107A1 (fr) 2006-04-12 2007-10-25 Spinal Motion, Inc. Dispositif vertebral posterieur et procede associe
KR101329496B1 (ko) * 2006-07-21 2013-11-13 바이오딜리버리 사이언시스 인터내셔널 인코포레이티드 향상된 흡수를 갖는 경점막 전달 장치
EP1897543A1 (fr) 2006-08-30 2008-03-12 Euro-Celtique S.A. Gaufre de buprénorphine pour la thérapie de substitution
GB0620661D0 (en) * 2006-10-18 2006-11-29 Pharmasol Ltd Novel compounds
US20090270438A1 (en) * 2006-10-18 2009-10-29 Clive Booles Novel compositions and formulations
GB2447016A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Buprenorphine/naloxone compositions
CN105833420A (zh) * 2008-06-23 2016-08-10 生物递送科学国际公司 多向粘膜给药装置及使用方法
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions

Also Published As

Publication number Publication date
KR20220047889A (ko) 2022-04-19
JP2015500886A (ja) 2015-01-08
UA118540C2 (uk) 2019-02-11
HK1203365A1 (en) 2015-10-30
IN2014DN06117A (fr) 2015-08-14
EA201992762A1 (ru) 2020-07-31
MX2014007350A (es) 2014-09-15
SG11201403075XA (en) 2014-07-30
KR102026321B1 (ko) 2019-09-27
MX2021012154A (es) 2021-11-03
AU2019202602A1 (en) 2019-05-02
AU2017258916A1 (en) 2017-11-30
AU2021202042A1 (en) 2021-04-29
CN110123792A (zh) 2019-08-16
BR112014015329A2 (pt) 2017-06-13
IL233075A0 (en) 2014-07-31
AU2012358308A1 (en) 2014-07-24
ZA201804381B (en) 2022-12-21
SG10202012743WA (en) 2021-01-28
MX362217B (es) 2019-01-09
AU2017258916B2 (en) 2019-01-17
WO2013096811A3 (fr) 2014-07-24
KR20140106720A (ko) 2014-09-03
EP2793870A2 (fr) 2014-10-29
CN104125828A (zh) 2014-10-29
EA201491046A1 (ru) 2014-11-28
EA034529B1 (ru) 2020-02-18
KR20210003313A (ko) 2021-01-11
KR20190110628A (ko) 2019-09-30
WO2013096811A2 (fr) 2013-06-27
IL285091A (en) 2021-08-31
EP2793870A4 (fr) 2016-02-17
JP6255349B2 (ja) 2017-12-27
SG10201710667YA (en) 2018-02-27
BR112014015329A8 (pt) 2017-06-13

Similar Documents

Publication Publication Date Title
US20240148639A1 (en) Transmucosal drug delivery devices for use in chronic pain relief
US20240108615A1 (en) Abuse-resistant mucoadhesive devices for delivery of buprenorphine
AU2021202042A1 (en) Transmucosal drug delivery devices for use in chronic pain relief
US20240130961A1 (en) Transmucosal drug delivery devices for use in chronic pain relief
US20210251983A1 (en) Methods of treatment with buprenorphine
NZ724912B2 (en) Transmucosal drug delivery devices for use in chronic pain relief
NZ622610B2 (en) Abuse-resistant mucoadhesive devices for delivery of buprenorphine

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20171219

EEER Examination request

Effective date: 20171219

FZDE Discontinued

Effective date: 20230704